Comparative Analysis of Biosimilar & Biosuperior Therapeutic Antibodies Presented in New Report

Published Date : Jun 14, 2016

ALBANY, NY, June 14, 2016 - has added a new report, ‘Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies - 2016 Update,’ to its offering. This report offers a comprehensive reports on the competitive landscape of biosimilar therapeutic antibodies as of May 2016. The first wave of biosimilar recombinant monoclonal antibodies has been analyzed by providing a comparative reports with corresponding originator antibodies and biosuperior acting against the same target. The following wave of promising biosimilar versions of the therapeutic antibodies predicted to lose their patent protection in the forecast period 2019 to 2023 has also been presented in this study.

Biosimilar antibodies are originator antibodies’ generic versions and have a similar amino acid sequence. The key difference between these two is that the latter are produced from different manufacturing processes and clones.

This report starts by presenting the sale of therapeutic antibodies in 2015. The section also includes an evaluation on the sale of biologics and therapeutic antibodies on the basis of class of products. The blockbuster therapeutic antibodies in 2015 have also been presented through this study. In addition, this part of the report provides information on the sale of anti-TNF, cancer, ophthalmic, other anti-inflammatory, and cardiometabolic and anti-infective antibodies in the same year.

In the next section of the report, a review of the biosimilar and biosuperior anti-TNF antibodies for 2016 has been presented. This section incorporates the recently approved indications and upside developments of Enbrel, Humira, Remicade, Lucentis, Avastin, Eylea, Rituxan/MabThera Herceptin, and Erbitux. These are the first wave originator therapeutic antibodies.

For Sample Copy, click here: 

In addition, the generation therapeutic antibodies against these targets are also presented, such as, Symponi, Cimzia, Cyramza, Perjeta, Arrzera. Moving further, this report on biosimilar and biosuperior therapeutic antibodies also throws light on the upcoming second wave of biosimilar antibody activities against originator therapeutic antibodies such as alemtuzumab, abatacept, denosumab, omalizumab, eculizumab, tocilizumab, ustekinumab, and pavilizumab. In addition, an reports on the biosuperior anti-TNF antibodies, non-antibody anti-TNF biosuperiors, and anti-TNF biosuperior antibodies has also been collated in this section.

Moving further, this report on the competitor reports of biosimilar and biosuperior therapeutic antibodies offers a review of the biosimilar and biosuperior anti-VEGF/R antibodies. Under this section, the marketed anti-VEGF/R products within oncology have also been presented. This part incorporates the sale and indication portfolio of Avastin, Cyramza, and Zaltrap.

Next, the anti-VEGF biosuperiors of Zaltrap and Avastin have been presented. The marketed anti-VEGF products within ophthalmology have also been highlighted under this section of the report. This includes the sale of Eylea and Lucentis from 2008 to 2015. An reports of the other anti-VEGF molecules within ophthalmology comes next in the report. The off-label usage of anti-VEGF within ophthalmology has also been compiled under this section of the study.

Some of the major companies presented in this report on the competitor reports of biosimilar and biosuperior therapeutic antibodies are AbbVie, AbClon, Ablynx, Baliopharm, Baxalta, Bayer, Daewoong Pharmaceutical Co., Daiichi Sankyo, Epirus Biopharmaceuticals, Esperance Pharmaceuticals, HanAll Pharmaceuticals, Hanwha Chemical Biologics Business, Jiangsu Simcere Pharmaceutical, Jiangsu T-mab Biopharma, and Kissei Pharmaceutical, among others.

To order report Call Toll Free: 866-997-4948 or send an email on